Cargando…

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

PURPOSE: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cazzaniga, Marina Elena, Danesi, Romano, Girmenia, Corrado, Invernizzi, Pietro, Elvevi, Alessandra, Uguccioni, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586706/ https://www.ncbi.nlm.nih.gov/pubmed/31065872 http://dx.doi.org/10.1007/s10549-019-05261-5

Ejemplares similares

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
por: Cazzaniga, Marina Elena, et al.
Publicado: (2023)

Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review
por: Elvevi, Alessandra, et al.
Publicado: (2023)

Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are
por: Rossi, Roberta Elisa, et al.
Publicado: (2022)

Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis
por: Massironi, Sara, et al.
Publicado: (2023)

Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms
por: Massironi, Sara, et al.
Publicado: (2023)

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
por: Massironi, Sara, et al.
Publicado: (2020)

Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies
por: Rossi, Roberta Elisa, et al.
Publicado: (2021)

Paradoxical association between dyspepsia and autoimmune chronic atrophic gastritis: Insights into mechanisms, pathophysiology, and treatment options
por: Rossi, Roberta Elisa, et al.
Publicado: (2023)

Epidemiology of Carbapenem Resistant Klebsiella pneumoniae Infections in Mediterranean Countries
por: Girmenia, Corrado, et al.
Publicado: (2016)

New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies
por: Girmenia, Corrado
Publicado: (2019)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Clinical challenge for gastroenterologists–Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review
por: Elvevi, Alessandra, et al.
Publicado: (2022)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Congenital factor VII deficiency: Multidisciplinary approach is the key to successful perioperative outcome
por: Tandale, Sushama Raghunath, et al.
Publicado: (2017)

Multidisciplinary uniform reporting for abdominal wall hernias: The key to a successful outcome
por: Kulkarni, Gaurav V., et al.
Publicado: (2023)

A metastatic ureteral tumor successfully treated with multidisciplinary therapy including radiotherapy
por: Kawaguchi, Yoshihiro, et al.
Publicado: (2023)

The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management
por: Roberto, Michela, et al.
Publicado: (2023)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

The HR Toolkit: An Indispensable Resource for Being a Credible Activist
por: Romano, Denise
Publicado: (2010)

HR TEAM
por: Brice, Maximilien
Publicado: (2015)

HR Organigramme
por: Favre, A
Publicado: (2001)

Organigramme HR
por: Favre, A
Publicado: (2011)

HR Explorer
por: Möller, M, et al.
Publicado: (1997)

Careers HR
por: Marcastel, Fabienne CERN Graphic Design service
Publicado: (2013)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2023)

Disproportion in T-cell subpopulations in immunodeficient mutant hr/hr mice
Publicado: (1979)

Multidisciplinary Treatment in Toxic Epidermal Necrolysis
por: Surowiecka, Agnieszka, et al.
Publicado: (2023)

Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
por: Breccia, Massimo, et al.
Publicado: (2011)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Invasive Candida Infections in Patients With Haematological Malignancies and Hematopoietic Stem Cell Transplant Recipients: Current Epidemiology and Therapeutic Options.
por: Girmenia, Corrado, et al.
Publicado: (2011)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Exploring the HR Universe
Publicado: (1997)

HV and HR CMOS
por: HEMPEREK, Tomasz
Publicado: (2016)

HR Public meeting
por: CATHERIN, Anne-Sylvie
Publicado: (2016)

Organigramme HR 2017
por: Cook, Anna
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nk8754ekng10ef62dab16iek52